Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GDC-0068 (ipatasertib) in Advanced Solid Tumors
jRCT2080222858Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipatasertib in Nonhematologic neoplasms and prostate cancer (PCa) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
ipatasertib
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080222858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222858.